For citations:

Ivashchenko D.V., Ryzhykova K.A., Sozaeva Zh.A., Zastrozhin M.S., Grishina E.A., Savchenko L.M., Bryun E.A., Sychev D.A. Pharmacogenetic evaluation of adverse events’ risk in patients with alcohol withdrawal syndrome taking bromdihydrochlorphenylbenzodiazepine: The role of CYP2C19 gene polymorphisms. World Journal of Personalized Medicine. 2017;1(1):18-26. (In Russ.) https://doi.org/10.14341/WJPM9262